Necrostatin-1 is a specific ATP-competitive allosteric inhibitor (EC50 = 180 nM) of death domain receptor-associated adaptor kinase (RIP1)¹. It selectively blocks a specific programmed cell death pathway, necroptosis, which leads to necrosis. While affecting this distinct cell death pathway, Necrostatin-1 does not present any perturbation of the Fas/TNFR triggered canonical apoptosis cascade. Necrostatin-1 inhibits the necrosis-induced RIP1 and RIP3 interactions in vitro² and reduces ischemic brain injury in a mouse model of stroke³.